FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221004306> ?p ?o ?g. }

• W4221004306 endingPage "2874" @default.
• W4221004306 startingPage "2869" @default.
• W4221004306 abstract "In partial response to the coronavirus disease 2019 (COVID-19) pandemic, countries around the world are conducting large-scale vaccination campaigns. Real-world estimates of vaccine effectiveness (VE) against the B.1.617.2 (Delta) variant are still limited. An outbreak in Ruili city of China provided an opportunity to evaluate VE against the Delta variant of two types of COVID-19 vaccines in use in China and globally – inactivated (CoronaVac and BBIBP-CorV) and adenovirus type 5 vectored (Convidecia) vaccines. We estimated VE using a retrospective cohort study two months after the Ruili vaccination campaign (median: 63 days). Close contacts of infected people (Chinese nationality, 18 years and above) were included to assess VE against symptomatic Covid-19, COVID-19 pneumonia, and severe COVID-19. We calculated the relative risks (RR) of the outcomes for unvaccinated compared with fully vaccinated individuals. We used logistic regression analyses to estimate adjusted VEs, controlling for gender and age group (18–59 years and 60 years and over).We compared unvaccinated and fully vaccinated individuals on duration of RT-PCR positivity and Ct value. There were 686 close contacts eligible for VE estimates. Adjusted VE of ad5-vectored vaccine was 61.5% (95% CI, 9.5–83.6) against symptomatic COVID-19, 67.9% (95%CI: 1.7–89.9) against pneumonia, and 100% (95%CI: 36.6–100) against severe/critical illness. For the two inactivated vaccines, combined VE was 74.6% (95% CI, 36.0–90.0) against symptomatic COVID-19, 76.7% (95% CI: 19.3–93.3) against pneumonia, and 100% (95% CI: 47.6–100) against severe/critical COVID-19. There were no statistically significant differences in VE between two inactivated vaccines for symptomatic COVID-19 and for pneumonia, nor were there statistically significant differences between inactivated and ad5-vectored VE in any of the three outcomes. The median durations of RT-PCR positivity were 17 days for fifteen people vaccinated with an inactivated vaccine, 18 days for forty-four people vaccinated with the Ad5 vectored vaccine, and 26 days for eleven unvaccinated individuals. These results provide reassuring evidence that the three vaccines are effective at preventing Delta-variant COVID-19 in short term following vaccination campaign, and are most effective at preventing more serious illness. The findings of reduced duration of RT-PCR positivity and length of hospital stay associated with full vaccination suggests potential saving of health-care system resources." @default.
• W4221004306 created "2022-04-03" @default.
• W4221004306 creator A5004833289 @default.
• W4221004306 creator A5008695404 @default.
• W4221004306 creator A5011015472 @default.
• W4221004306 creator A5015873777 @default.
• W4221004306 creator A5039288852 @default.
• W4221004306 creator A5040158379 @default.
• W4221004306 creator A5040888626 @default.
• W4221004306 creator A5045083507 @default.
• W4221004306 creator A5047632877 @default.
• W4221004306 creator A5049576249 @default.
• W4221004306 creator A5063333893 @default.
• W4221004306 creator A5064619389 @default.
• W4221004306 creator A5073164485 @default.
• W4221004306 creator A5077148546 @default.
• W4221004306 creator A5084247462 @default.
• W4221004306 creator A5086722817 @default.
• W4221004306 creator A5087611125 @default.
• W4221004306 creator A5089483737 @default.
• W4221004306 date "2022-05-01" @default.
• W4221004306 modified "2023-10-17" @default.
• W4221004306 title "Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021" @default.
• W4221004306 cites W3027829318 @default.
• W4221004306 cites W3177080207 @default.
• W4221004306 cites W3179399516 @default.
• W4221004306 cites W3192739702 @default.
• W4221004306 cites W3194599195 @default.
• W4221004306 cites W3200717704 @default.
• W4221004306 cites W3209726765 @default.
• W4221004306 cites W3215124885 @default.
• W4221004306 cites W4200135346 @default.
• W4221004306 cites W4213221851 @default.
• W4221004306 cites W4221081069 @default.
• W4221004306 cites W4285606826 @default.
• W4221004306 doi "https://doi.org/10.1016/j.vaccine.2022.03.067" @default.
• W4221004306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35400561" @default.
• W4221004306 hasPublicationYear "2022" @default.
• W4221004306 type Work @default.
• W4221004306 citedByCount "21" @default.
• W4221004306 countsByYear W42210043062022 @default.
• W4221004306 countsByYear W42210043062023 @default.
• W4221004306 crossrefType "journal-article" @default.
• W4221004306 hasAuthorship W4221004306A5004833289 @default.
• W4221004306 hasAuthorship W4221004306A5008695404 @default.
• W4221004306 hasAuthorship W4221004306A5011015472 @default.
• W4221004306 hasAuthorship W4221004306A5015873777 @default.
• W4221004306 hasAuthorship W4221004306A5039288852 @default.
• W4221004306 hasAuthorship W4221004306A5040158379 @default.
• W4221004306 hasAuthorship W4221004306A5040888626 @default.
• W4221004306 hasAuthorship W4221004306A5045083507 @default.
• W4221004306 hasAuthorship W4221004306A5047632877 @default.
• W4221004306 hasAuthorship W4221004306A5049576249 @default.
• W4221004306 hasAuthorship W4221004306A5063333893 @default.
• W4221004306 hasAuthorship W4221004306A5064619389 @default.
• W4221004306 hasAuthorship W4221004306A5073164485 @default.
• W4221004306 hasAuthorship W4221004306A5077148546 @default.
• W4221004306 hasAuthorship W4221004306A5084247462 @default.
• W4221004306 hasAuthorship W4221004306A5086722817 @default.
• W4221004306 hasAuthorship W4221004306A5087611125 @default.
• W4221004306 hasAuthorship W4221004306A5089483737 @default.
• W4221004306 hasBestOaLocation W42210043061 @default.
• W4221004306 hasConcept C116675565 @default.
• W4221004306 hasConcept C126322002 @default.
• W4221004306 hasConcept C151956035 @default.
• W4221004306 hasConcept C159047783 @default.
• W4221004306 hasConcept C167135981 @default.
• W4221004306 hasConcept C22070199 @default.
• W4221004306 hasConcept C2777914695 @default.
• W4221004306 hasConcept C2779134260 @default.
• W4221004306 hasConcept C3008058167 @default.
• W4221004306 hasConcept C524204448 @default.
• W4221004306 hasConcept C71924100 @default.
• W4221004306 hasConcept C89623803 @default.
• W4221004306 hasConceptScore W4221004306C116675565 @default.
• W4221004306 hasConceptScore W4221004306C126322002 @default.
• W4221004306 hasConceptScore W4221004306C151956035 @default.
• W4221004306 hasConceptScore W4221004306C159047783 @default.
• W4221004306 hasConceptScore W4221004306C167135981 @default.
• W4221004306 hasConceptScore W4221004306C22070199 @default.
• W4221004306 hasConceptScore W4221004306C2777914695 @default.
• W4221004306 hasConceptScore W4221004306C2779134260 @default.
• W4221004306 hasConceptScore W4221004306C3008058167 @default.
• W4221004306 hasConceptScore W4221004306C524204448 @default.
• W4221004306 hasConceptScore W4221004306C71924100 @default.
• W4221004306 hasConceptScore W4221004306C89623803 @default.
• W4221004306 hasIssue "20" @default.
• W4221004306 hasLocation W42210043061 @default.
• W4221004306 hasLocation W42210043062 @default.
• W4221004306 hasLocation W42210043063 @default.
• W4221004306 hasOpenAccess W4221004306 @default.
• W4221004306 hasPrimaryLocation W42210043061 @default.
• W4221004306 hasRelatedWork W3012050440 @default.
• W4221004306 hasRelatedWork W3022913415 @default.
• W4221004306 hasRelatedWork W3049611100 @default.
• W4221004306 hasRelatedWork W3108471389 @default.
• W4221004306 hasRelatedWork W3139444595 @default.
• W4221004306 hasRelatedWork W3189635965 @default.

• next